K-ras Oncogene Codon 12 Point Mutations in Testicular Cancer

by Maaret Ridanpää, Ragnhild A. Lothe, Agneta Önfelt, Sophie Fosså, Anne-Lise Børresen, and Kirsti Husgafvel-Pursiainen

A significant association between N-ras oncogene activating point mutations and testicular cancer has recently been reported. We have studied DNA samples from the blood and fresh tumor tissues of 17 Norwegian testicular cancer patients (11 seminomas/6 nonseminomas). Point mutations in K-ras-2 and N-ras exons 1 and 2 were studied by denaturing gradient gel electrophoresis (DGGE) and by oligonucleotide hybridization. No N-ras mutations were detected in these tumor samples, but two K-ras-2 exon 1 mutations were found in two of the seminoma tumors (stage I and II tumors) using the DGGE technique. The mutations were confirmed by dot blotting and oligonucleotide hybridization and identified as a G→T and a G→A point mutation in K-ras-2 codon 12, leading to a valine and a serine substitution, respectively. All the white blood cell DNAs were negative. As a positive control for DGGE screening, we ran two plasmid constructs carrying human N-ras exon 2 sequences with mutations. To study the role of ras gene activation in testicular cancer, a larger tumor sample population will be investigated.

Introduction

Testicular cancer is one of the most frequent cancers among young men. A higher risk of testicular cancer has been associated with certain subpopulations, e.g., men of higher socioeconomic status and some occupational groups such as paper and printing workers, professionals, and administrators (1). Other anatomic, genetic, and environmental risk factors also exist.

The most common activated oncogenes in human cancers are ras oncogenes (2). This oncogene family contains three closely related cellular genes: K-ras-2, H-ras-1, and N-ras (3). The ras genes are almost exclusively activated by single base-pair substitutions (4), most frequently in codons 12, 13, or 61. Different members of the ras oncogene family are activated in various types of cancer (2,5). In testicular cancer, N-ras point mutations have frequently been detected in codons 12 and 61 (6,7). However, Mulder et al. (6) also reported K-ras-2 codon 12 base substitutions in a few of the cases.

We studied K-ras-2 and N-ras mutations in samples from 17 Norwegian testicular cancer patients by denaturing gradient gel electrophoresis (DGGE) and by dot blotting and oligonucleotide hybridization (8,9). The combination of these techniques has turned out to be suitable for rapidly screening for mutations in ras oncogenes (10). DGGE is based on the ability of DNA to melt in different sequence-dependent domains. Theoretically, one base pair substitution in a lower melting domain is enough to change the melting behavior of a DNA sequence (11-13).

Materials and Methods

DNA samples from the peripheral blood and fresh tumor tissue of 17 Norwegian testicular cancer patients were studied. The patients were 22–53 years old at the time of diagnosis, and they are a subgroup of cases already described by Lothe et al. (14). According to a light microscopic diagnosis, 11 of the patients had a unilateral seminoma and 6 had a unilateral nonseminoma.

K-ras-2 and N-ras exons 1 and 2 were amplified separately by the polymerase chain reaction (PCR) using AmpliTaq-DNA polymerase (Cetus). In each of the PCR products, one of the primers had a GC-rich oligonucleotide sequence of 40 base pairs (a GC-clamp), which was introduced at one end of the amplified sequences (15,16). Sequences for the primers are given elsewhere (Ridanpää and Husgafvel-Pursiainen, submitted). The length of the PCR products varied between 150 and 175 base-pairs.

Aliquots of the PCR products were analyzed in denaturing gradient gel electrophoresis (DGGE). Perpendicular and parallel gels were run using 7.5% polyacrylamide gels containing a linear gradient of chemical denaturants. In
the perpendicular gels, the gradient was 0–50% and in the parallel gels it was 25–40% (100% denaturant = 7 M urea and 40% formamide). All gels were run at 60°C in a bath of Tris-acetate-EDTA (TAE) buffer at pH 8.0. The gels were stained with ethidium bromide in distilled water before photographing under UV light.

Two plasmids carrying a single base-pair substitution in human N-ras codon 61 (CAA→AAA and CAA→CAC) were constructed (16). After in vitro amplification, the N-ras mutant sequences were run in DGGE as a control for the separation of the mutant bands from the wild-type ones. Specimens from the same PCR products were dot blotted on nylon membranes (Hybond) with a set of positive control DNAs for activating point mutations in K-ras-2 and N-ras in codons 12, 13, and 61 (Clonetech Laboratories). 32P-end-labeled oligonucleotide probing, hybridization, and washing procedures were done according to the manufacturer’s recommendation. Autoradiography films (Amersham) were exposed at −70°C using intensifying screens.

Results

Among 11 seminomas, there were two cases (stage I and II) that were observed to carry a K-ras-2 exon 1 mutation by DGGE. A clear separation between the homoduplex wild-type band and the mutant homoduplex bands were obtained. By oligonucleotide hybridization, these two mutations were identified to be a G→T transversion (glycine to valine substitution) and a G→A transition (serine substituted for glycine) in K-ras-2 codon 12 (Fig. 1). The rest of the seminoma samples and all of the nonseminoma samples showed neither N-ras nor other K-ras-2 mutations (Table 1).

The two in vitro amplified N-ras sequences each carrying a single base-pair substitution in codon 61 (CAA→AAA, CAA→CAC) gave a good separation in the denaturing gradient gels (Fig. 2). In tumor samples, in addition to the well-separated homoduplex bands, heteroduplexes were seen on the denaturing gradient gels. The heteroduplex bands of the valine mutant displayed greater separation than the heteroduplex bands of the serine mutant, thus facilitating the identification of the mutants.

Discussion

N-ras point mutations in codons 12 and 61 have been detected in 4/14 (6) and 20/31 (7) tumors of testicular cancer. In addition, Mulder et al. (6) reported two K-ras-2 codon 12 mutations in a group of 14 testicular cancers. In the present study, the only ras gene mutations found in the fresh testicular tumor samples from 17 patients were those in K-ras-2 codon 12. Both of the K-ras-2 mutations were detected in seminoma tumors, one being a stage I and the other a stage II tumor. This is in accordance with the reported higher incidence of ras gene mutations in seminoma as compared to nonseminoma tumors (7).

Compared to our findings in lung cancer, using a similar approach (10), the observed K-ras-2 mutation frequency in

| Histological diagnosis | No. of tumors | Amino acid substitution |
|------------------------|---------------|-------------------------|
| Seminoma               | 11            | Serine-12               |
|                        |               | Valine-12               |
| Nonseminoma            |               |                         |
| Embryonal carcinoma    | 3             | None                    |
| Endodermal sinus tumor | 2             | None                    |
| Mature teratoma        | 1             | None                    |

*No K-ras-2 exon 2 (condon 61) or N-ras mutations were detected.

Figure 1. Detection of point mutations in K-ras-2 exon 1 by denaturing gradient gel electrophoresis. Testicular tumor samples on a parallel gel (denaturing concentration 25–40%). (A) Lane 1 shows a mutation (codon 12 valine, GGT→GTG). (B) Lane 2 shows a mutation (codon 12 serine, GGT→AGT). In both figures the other lanes represent wild-type.

Figure 2. Detection of point mutations in N-ras exon 2 in a parallel gel electrophoresis (denaturing gradient 25–40%). (Lane 1) Positive control sequence carrying codon 61 lysine (AAA); (Lane 2) positive control sequence carrying codon 61 histidine-2 (CAC); (Lane 3) N-ras exon 2 codon 61 wild-type (CAA).
testicular cancer seems to be much lower. In lung adenocarcinoma, ras gene activation seems to occur in early stages of tumor development and has been associated with poor prognosis (17). Most of the mutations found in lung adenocarcinomas are reported to be G→T transversions in K-ras-2 (10, 15) and the mutation type appears to be associated with smoking (18). In the literature, however, no such qualitative predominance in the types of base-pair substitutions in K-ras-2 or N-ras genes has been found in testicular cancer (6, 7). The amount of cancer, however, is too small to draw any firm conclusions about the nature and the frequency of the ras oncogene mutations in testicular cancer. To further elucidate the role and type of ras gene mutations in testicular cancer, we are now in the process of cases investigating a larger set of tumor samples.

The authors acknowledge the excellent technical assistance of Taula Suutiala and Terttu Kaustia, for revising the English of this paper. The study was financially supported by The Nordic Fund for Technology and Industrial Development (P 88134), The Norwegian Cancer Society and The Swedish Work Environment Fund.

REFERENCES

1. Swerdlow, A. J., Douglas, A. J., Hutty, S. R. A., and Smith, P. G. Cancer of the testis, socioeconomic status, and occupation. Br. J. Ind. Med. 48: 670–674 (1991).
2. Bos, J. L. ras Oncogenes in human cancer. Cancer Res. 49: 4682–4689 (1989).
3. Bos, J. L. The ras gene family and human carcinogenesis. Mutat. Res. 195: 255–271 (1988).
4. Reddy, E. P., Reynolds, R. K., Santos, E., and Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149–152 (1982).
5. Barbacid, M. ras Oncogenes: their role in neoplasia. Eur. J. Clin. Invest. 20: 225–235 (1990).
6. Mulder, M. P., Keijzer, W., Verkerk, A., Boot, A. J. M., Prins, E. F., Splinter, T. A. W., and Bos, J. L. Activated ras genes in human seminoma: evidence for tumor heterogeneity. Oncogene 4: 1345–1351 (1989).
7. Ganguly, S., Murty, V. V. V. S., Samaniego, F., Reuter, V. E., Bosl, G. J., and Chaganti, R. S. K. Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction. Genes Chrom. Cancer 1: 226–232 (1990).
8. Bos, J. L., Verlaan-de Vries, M., Janssen, A. M., Veeneman, G. H., Van Boom, J. H., and Van der Eb, A. J. Three different mutations in codon 61 of the human N-ras oncogene detected by oligonucleotide hybridization. Nucleic Acids Res. 12: 9155–9162 (1984).
9. Verlaan-de Vries, M., Bogaard, M. E., Van Boom, J. H., Van der Eb, A. J., and Bos, J. L. A dot-blot screening procedure for mutated ras oncogenes using synthetic oligonucleotides. Gene 50: 313–320 (1986).
10. Husgafvel-Pursiainen, K., Ridanpää, M., Hackman, P., Anttila, S., Karjalainen, A., Önfelt, A., Barr resend, A.-L., and Vainio, H. Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction. Environ. Health Perspect. 98: 183–185 (1992).
11. Fisher, S. G., and Lerman, L. S. DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: correspondence with melting theory. Proc. Natl. Acad. Sci. U.S.A. 80: 1579–1583 (1983).
12. Lerman, L. S., Fischer, S. G., Hurley, I., Silverstein, K., and Lumelsky, N. Sequence-determined DNA separations. Annu. Rev. Biophys. Bior. Eng. 13: 399–423 (1984).
13. Myers, R. M., Maniatis, T., and Lerman, L. S. Detection and localization of single base changes by denaturing gradient gel electrophoresis. Methods Enzymol. 156: 501–527 (1987).
14. Lothe, R. A., Fosså, S. D., Stenwig, A. E., Nakamura, Y., White, R., Burressen, A.-L., and Bragger, A. Loss of 3p or 11p alleles is associated with testicular cancer tumors. Genomics 5: 134–138 (1989).
15. Sheffield, V. C., Cox, D. R., Lerman, L. S., and Myers, R. M. Attachment of a 40-base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results on improved detection of single-base changes. Proc. Natl. Acad. Sci. U.S.A. 86: 222–226 (1989).
16. Burvall, K., Ridanpää, M., Husgafvel-Pursiainen, K., and Önfelt, A. Separation of transforming N-ras mutations in codons 12, 13 and 61 by denaturing gradient gel electrophoresis: investigation based on a set of phagemid constructs. Mutat. Res., in press.
17. Siebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, J. L. M., Wagenaar, S. S., Vandeverscharen, R. G. J. R. A., van Zanwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, M. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 323: 561–565 (1990).
18. Siebos, R. J. C., Hruban, R. H., Dalesio, O., Mooi, W. J., Offerhaus, G. J. A., and Rodenhuis, S. K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Natl. Cancer Inst. 83: 1024–1027 (1991).